- Home
- CCIF vs ELDN Comparison
CCIF vs ELDN Comparison
Compare CCIF & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCIF | ELDN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.4M | 120.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CCIF | ELDN |
|---|---|---|
| Price | $4.77 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 76.9K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.43 | $1.35 |
| 52 Week High | $10.16 | $4.98 |
Technical Indicators
Market Signals| Indicator | CCIF | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 36.71 |
| Support Level | $4.60 | $1.47 |
| Resistance Level | $4.94 | $1.75 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 28.77 | 33.33 |
Price Performance
Historical ComparisonAbout CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.